Project Grant R01HL171377
Award Date
8/6/24
Completion Date
4/30/28
Dollars Obligated
$694K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $579,425 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Case Western Reserve University (CWRU) to develop and improve the delivery of gene therapy treatments, including adeno-associated viral (AAV) and nanoparticle (NP) therapies, to the heart. The goal is to enhance the efficacy and safety of these therapies for treating cardiomyopathies, which are highly prevalent disorders of the cardiac muscle that often...
This $704,635 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, is funding research to develop optimized adeno-associated virus (AAV) vector constructs for gene therapy of hemophilia. The primary awardee, the University of Florida, is conducting research to combine capsid and genome modifications to AAV3 vectors to improve their transduction efficiency and therapeutic expression in human...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $719,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Rector & Visitors of the University of Virginia. The grant supports research to develop a novel approach for mitigating intimal hyperplasia, a common complication of vascular surgery, by targeting the enzyme ALDH1A3. The researchers aim to elucidate the role of ALDH1A3 in endothelial cell...
This $726,205 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop and validate a new super-resolution intravascular ultrasound (SR-IVUS) technology. The goal is to enable effective imaging of the vasa vasorum (VV) network and thin fibrous cap of vulnerable atherosclerotic plaques to assess plaque vulnerability. The key products to be delivered include: A dual mode SR-IVUS catheter and system integrating a 60 MHz...
This R21 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to develop and test novel nanobody therapeutics that can disrupt Connexin 43 (Cx43)-mediated pathological proliferation of smooth muscle cells. The $236,833 award to Virginia Polytechnic Institute & State University (Virginia Tech) will fund research to generate and validate Cx43-targeting nanobodies as potential...
The $814,209 federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel nanoparticle-based gene therapy approach for in vivo hematopoietic stem cell (HSC) modification. The project aims to optimize nanoparticle formulations that can deliver next-generation gene-editing agents and target the HSC-enriched cell population identified in the researchers' prior...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) supports research to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes that influence cardiovascular disease (CVD) risk. The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association studies (GWAS) to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $317,285 to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following a myocardial infarction. The project aims to finalize a prototype catheter for epicardial gene painting to enable transmural ventricular gene transfer, verify targeted transgene expression, and evaluate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,368,153 to The Johns Hopkins University to evaluate the safety and efficacy of using adeno-associated viral (AAV) vectors containing a truncated version of the CFTR gene (AAV1-CBD27-264) for cystic fibrosis gene therapy. The research will involve studies in rhesus macaques and a ferret model bearing the F508 CFTR mutation to assess the...
This $698,017 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a cardiovascular disease (CVD) vaccine targeting the S100A9 protein and potentially PCSK9 cholesterol regulation. The University of California, San Diego (UCSD) is using the 4-year grant to: Develop S100A9-based vaccine candidates using plant virus-like particles and evaluate their ability to reduce S100A9 levels,...